返回 
加入收藏
我国创新药进入医保目录的障碍与对策
x
请在关注微信后，向客服人员索取文件
| 篇名： | 我国创新药进入医保目录的障碍与对策 |
| TITLE： | |
| 摘要： | 目的：为我国创新药能顺利进入医保目录，促进我国医药产业快速发展提供参考。方法：笔者在对国内外创新药进入医保目录的相关管理政策进行研究的基础上，深入剖析我国创新药进入医保目录的政策障碍，并提出相应的改革建议。结果与结论：我国医保政策中存在着医保目录遴选依据不够客观、医保审评专家的遴选机制使审评结果容易受到个人主观意愿的影响、医保目录调出机制缺失、创新药进入医保目录等待时间过长、创新药谈判机制不健全等问题。建议强制要求制药企业提供药物经济学评价的相关数据、增强医保目录审评专家组的独立性和多元化、定期对医保目录中的药物进行二次评价、为创新药进入医保目录开设“绿色通道”、建立全国统一的药品价格谈判机制以及医保信息数据库。 |
| ABSTRACT： | OBJECTIVE： To provide a reference for innovative drugs to enter the health insurance directory smoothly and promote the rapid development of pharmaceutical industry in China. METHODS： Based on related policy study of foreign and domestic innovative drugs entering the health insurance directory， the policy barriers of innovative drugs entering the health insurance directory were analyzed and the countermeasures were put forward. RESULTS & CONCLUSIONS： In China， the foundation of drug selection was not objective enough； the review results were so vulnerable to subjective views because of the experts selection mechanism； the health insurance directory deletion mechanism was deficient； the waiting time for innovative drugs entering the health insurance directory was too long； innovative drugs negotiation mechanism was imperfect， etc. It is recommended that forcibly requiring pharmaceutical companies should provid the related data about pharmacoeconomic evaluation； the independence and pluralism of the expert group should be enhanced； drugs in the health insurance directory should be secondarily evaluated regularly； the innovative drugs should be given the green channel； innovative drug price negotiation rules should be unified to promote drug information sharing. |
| 期刊： | 2017年第28卷第4期 |
| 作者： | 段晓托，连桂玉，贾耀珠 |
| AUTHORS： | DUAN Xiaotuo，LIAN Guiyu，JIA Yaozhu |
| 关键字： | 医保目录；创新药；政策 |
| KEYWORDS： | Health insurance directory； Innovative drugs； Policy |
| 阅读数： | 629 次 |
| 本月下载数： | 15 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
